Phylloceuticals, Inc., a biotechnology company dedicated to revolutionizing the production of therapeutic proteins using its proprietary plant-based technology, today announced the appointment of Jane H. Hollingsworth to its Board of Directors.
Ms. Hollingsworth is a seasoned life sciences executive and investor with extensive experience founding, building, and leading high-growth biopharmaceutical companies. She is a founding Managing Partner of Militia Hill Ventures (MHV), a firm dedicated to founding and growing innovative life sciences companies. At MHV, she co-founded and served as executive chair of Spirovant Sciences, a respiratory-focused gene therapy company acquired by Sumitomo Pharma, and Eliksa Therapeutics, a regenerative medicine company focused on rare diseases. She also served as CEO and executive chair of Immunome, Inc. (NASDAQ: IMNM), a cancer immunotherapy company.
Prior to MHV, Ms. Hollingsworth co-founded and led NuPathe Inc., a neuroscience-focused company acquired by Teva, and co-founded and served as EVP of Auxilium Pharmaceuticals, a urology and rare disease company acquired by Endo Pharmaceuticals.
“We are delighted to welcome Jane to our Board of Directors,” said Susan Stipa, CEO of Phylloceuticals. “Jane’s proven track record in creating and scaling life sciences companies, combined with her deep understanding of strategy and innovation in our industry, will be invaluable as we advance our mission of transforming plant-based science into impactful medicines for patients,” she added.
“I’m excited to join Phylloceuticals as they advance innovation in plant-derived therapeutics,” said Jane Hollingsworth. “Their proprietary technology and manufacturing expertise have the potential to meaningfully reduce development timelines and risk, while expanding access to advanced biologics for patients who need them.”